Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab vs placebo after neoadjuvant chemoradiotherapy and surgery in resected esophageal or gastroesophageal junction cancer
CTR20180183Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab in esophageal cancer, esophagogastric junction cancer, sponsored by Bristol Myers Squibb. Started Mar 2018; status: completed.
02
Drugs
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on CTR20180183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180183.